Beyond the crowded AI trade, smart money sees opportunity in overlooked sectors. These include healthcare, which is at a 30-year low in relative valuation, and companies serving the middle-income consumer, a segment poised to benefit from upcoming tax reforms.
Related Insights
When evaluating AI startups, don't just consider the current product landscape. Instead, visualize the future state of giants like OpenAI as multi-trillion dollar companies. Their "sphere of influence" will be vast. The best opportunities are "second-order" companies operating in niches these giants are unlikely to touch.
Instead of selling software to traditional industries, a more defensible approach is to build vertically integrated companies. This involves acquiring or starting a business in a non-sexy industry (e.g., a law firm, hospital) and rebuilding its entire operational stack with AI at its core, something a pure software vendor cannot do.
Recent job growth is overwhelmingly concentrated in healthcare services (83% of new NFP jobs) for an aging population. This, combined with an AI capex bubble, reveals a non-dynamic, 'K-shaped' economy where 'Main Street' stagnates and growth depends on narrow, unsustainable drivers.
Despite the hype, YC's focus isn't just on pure AI startups. The accelerator is backing a diverse portfolio of companies in healthcare, finance, and deep tech, using AI as a disruptive tool to rewrite the rules of these traditional, 'dusty' industries, much like the internet did.
If AI is truly transformational, its greatest long-term value will accrue to non-tech companies that adopt it to improve productivity. Historical tech cycles show that after an initial boom, the producers of a new technology are eventually outperformed by its adopters across the wider economy.
In an overvalued market, stable pharmaceutical companies with strong dividends and modest growth can serve as a safe place to park capital. They offer a yield comparable to T-bills but with added upside from growth, acting as a defensive equity holding.
Current market multiples appear rich compared to history, but this view may be shortsighted. The long-term earnings potential unleashed by AI, combined with a higher-quality market composition, could make today's valuations seem artificially high ahead of a major earnings inflection.
The AI investment case might be inverted. While tech firms spend trillions on infrastructure with uncertain returns, traditional sector companies (industrials, healthcare) can leverage powerful AI services for a fraction of the cost. They capture a massive 'value gap,' gaining productivity without the huge capital outlay.
When a few high-flying stocks like the 'Mag-7' dominate the market, capital is pulled from other sectors, creating cyclical valuation discounts. Stable industries like healthcare can become as cheap relative to the S&P 500 as they were during the 2000 tech bubble, presenting a contrarian investment opportunity.
Unlike labor-dependent services that get more expensive, prescription drugs offer a unique societal ROI because they eventually go generic and become cheaper. This deflationary aspect is a powerful, underappreciated argument for investing in drug development, as successful medicines provide compounding value to society over time.
